Phase I study of TAK-659, an investigational, dual SYK/FLT3 iinhibitor, in patients with B-cell lymphoma
Authors
Gordon, LIKaplan, B
Popat, R
Burris, HA
Ferrari, S
Madan, S
Patel, MR
Gritti, G
El-Sharkawi, D
Chau, I
Radford, John A
Perez, de Oteyza, J
Luigi, Zinzani, P
Iyer, S
Townsend, W
Karmali, R
Miao, H
Proscurshim, I
Wang, S
Wu, Y
Stumpo, K
Shou, Y
Carpio, C
Bosch, F
Affiliation
Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, and the Robert H. Lurie Comprehensive Cancer CenterIssue Date
2020
Metadata
Show full item recordCitation
Gordon LI, Kaplan JB, Popat R, Burris HA, Ferrari S, Madan S, et al. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-cell Lymphoma. Clin Cancer Res. 2020.Journal
Clinical Cancer ResearchDOI
10.1158/1078-0432.ccr-19-3239PubMed ID
32327472Additional Links
https://dx.doi.org/ 10.1158/1078-0432.ccr-19-3239Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1078-0432.ccr-19-3239
Scopus Count
Collections
Related articles
- Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
- Authors: Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, Kelly KR, Copeland AR, Akins A, Clancy MS, Gong L, Wang J, Ma A, Viner JL, Oki Y
- Issue date: 2016 May
- Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
- Authors: Song Y, Cao J, Zhang Q, Li C, Qiu L, Qi J, Zhang H, Li W, Liu L, Jing H, Zhou K, Zhang W, Zhang L, Li D, Zou L, Yang H, Qian W, Zhou H, Hu J, Yin H, Fu S, Fan S, Xu Q, Wang J, Jia X, Dai G, Su W, Zhu J
- Issue date: 2024 Jul 1
- Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
- Authors: Friedberg JW, Mahadevan D, Cebula E, Persky D, Lossos I, Agarwal AB, Jung J, Burack R, Zhou X, Leonard EJ, Fingert H, Danaee H, Bernstein SH
- Issue date: 2014 Jan 1
- Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.
- Authors: Coffey GP, Feng J, Betz A, Pandey A, Birrell M, Leeds JM, Der K, Kadri S, Lu P, Segal J, Wang YL, Michelson G, Curnutte JT, Conley PB
- Issue date: 2019 Feb 15
- Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
- Authors: Michot JM, Bouabdallah R, Vitolo U, Doorduijn JK, Salles G, Chiappella A, Zinzani PL, Bijou F, Kersten MJ, Sarmiento R, Mosulen S, Mendez C, Uttamsingh S, Pourdehnad M, Hege K, Chen T, Klein C, Hagner PR, Nikolova Z, Ribrag V
- Issue date: 2020 Sep